IBIO
iBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.76
−0.81%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.76
From 52W high−75.24%
Volume352116.00
Market cap$48.88M
P/E (TTM)—
P/S (TTM)488.8x
Div yield—
Key dataOct 19, 2026
Open
$0.76
From 52W high
−75.24%
Volume
352116.00
Market cap
$48.88M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.2x
P/E (TTM)
—
RSI (14)
19.3
MomentumView details →
1D Return
−0.81%
YTD Return
−60.43%
SummaryUpdated Jun 1, 2026
iBio, Inc. (NASDAQ:IBIO) is a biotechnology company founded in 2008 and headquartered in Bryan, Texas. The company operates as a contract development and manufacturing organization while simultaneously developing its own therapeutic pipeline. iBio has evolved from a plant-based manufacturing platform company into an immuno-oncology focused biotechnology firm, particularly following its 2022 acquisition of RubrYc's AI-driven drug discovery platform. The company trades on public markets and serves both internal drug development programs and external pharmaceutical clients through its specialized manufacturing and development services.
Similar companies
Latest newsMore news →
iBio, Inc. reported its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress, including the initiation of the Phase 1 clinical trial of IBIO-600.53d agoiBio, Inc. appointed endocrinologist Molly Carr, M.D., as Chief Medical Officer on August 4, 2026, to lead its global clinical strategy, medical affairs, and regulatory initiatives.77d agoiBio dosed the first participant in a Phase 1 clinical trial of IBIO-600 for obesity, becoming a clinical-stage company.140d ago